WHAT IS CLAIMED IS:

1. Use of a pharmaceutical composition comprising epetraborole or a hydrate, solvate, or salt thereof, in the manufacture of a medicament for treating a non-tuberculosis *Mycobacteria* infection or a non-tuberculosis *Mycobacteria*-associated disease in a human, wherein the medicament is to be administered with ethambutol,
thereby treating the non-tuberculosis *Mycobacteria* infection in the human.

2. The use of claim **1**, wherein a rifamycin, or a salt thereof, or rifamycin, or a salt thereof, is to be further administered to the human, optionally, wherein the rifamycin is rifampicin (rifampin), rifabutin, rifapentine, or rifaximin.

3. The use of claim **1** or **2**, wherein a macrolide, or a salt thereof, is to be further administered to the human, optionally, wherein the macrolide is clarithromycin or azithromycin.

4. The use of claim **1** or **2**, wherein the epetraborole is a salt of the epetraborole, and the salt is a pharmaceutically acceptable salt, optionally, wherein the epetraborole is epetraborole hydrochloride.

5. The use of claim **1** or **2**, wherein the non-tuberculosis *Mycobacteria* is rapidly growing, optionally, wherein the non-tuberculosis *Mycobacteria* is rapidly growing and is selected from the group consisting of *M. abscessus*, *M. arabiense*, *M. aromaticivorans*, *M. bacteremicum*, *M. barrassiae*, *M. bourgelatii*, *M. celeriflavum*, *M. chelonae, M. crocinum*, *M. franklinii*, *M. fukienense*, *M. hippocampi*, *M. insubricum*, *M. iranicum*, *M. litorale*, *M. llatzerense*, *M. monacense*, *M. pallens*, *M. rufum*, *M. rutilum*, *M. salmoniphilum*, *M. sediminis*, and *Mycobacterium setense; or* wherein the non-tuberculosis *Mycobacteria* is slowly growing, optionally, wherein the non-tuberculosis *Mycobacteria* is slowly growing, and is selected from the group consisting of *M. algericum*, *M. alsiense*, *M. arosiense*, *M. bouchedurhonense*, *M. engbaekii*, *M. europaeum*, *M. fragae*, *M. heraklionense*, *M. indicus pranii*, *M. koreense*, *M. kumamotonense*, *M. kyorinense*, *M. lepromatosis*, *M. liflandii*, *M. longobardum*, *M. mantenii*, *M. marseillense*, *M. minnesotense*, *M. noviomagense*, *M. paraffinicum*, *M. paragordonae*, *M. parakoreense*, *M. paraseoulense*, *M.*

paraterrae, *M. riyadhense*, *M. senuense*, *M. seoulense*, *M. sherrisii*, *M. shigaense*, *M. shinjukuense*, *M. simulans*, *M. sinense*, *M. stomatepiae*, *M. timonense*, *M. vulneris*, and *M. yongonense*; or

optionally, wherein the non-tuberculosis *Mycobacteria* is selected from the group consisting of *M. abscessus*, *M. avium* complex (MAC), M. *chelonae*, *M. fortuitum*, *M. gordonae*, *M. kansasii*, *M. mucogenicum*, *M. peregrinum*, and M. *xenopi*; or

optionally, wherein the non-tuberculosis *Mycobacteria* is selected from the group consisting of *M. abscessus*, *M. avium* complex (MAC), *M. fortuitum* complex, *M. gordonae*, *M. kansasii*, and *M. xenopi*; or

optionally, wherein the non-tuberculosis *Mycobacteria* is *Mycobacterium avium* complex; or

optionally, wherein the non-tuberculosis *Mycobacteria* is *M. avium, M. intracellulare, M. marseillaise, M. timonense, M. bouchedurhonense, M. colombiense, M. vulneris*, and *M. chimaera*; or

optionally, wherein the non-tuberculosis Mycobacteria is *M. intracellulare*; or

optionally, wherein the non-tuberculosis Mycobacteria is *M. intracellulare* subsp. *intracellulare* or *M. intracellulare* subsp. *chimaera*; or

optionally, wherein the non-tuberculosis *Mycobacteria* is *M. avium*; or

optionally, wherein the non-tuberculosis *Mycobacteria* is *M. avium* subsp. *avium*, *M. avium* subsp. *hominissium, M. avium subsp. silvaticum*, or *M. avium* subsp. *paratuberculosis*.

6. The use of claim **1** or **2**, wherein the human further has a disease which is cystic fibrosis, chronic obstructive pulmonary disease, or chronic thromboembolic pulmonary hypertension; or wherein the human further has a disease which is an interstitial lung disease, which is an interstitial lung disease, post-inflammatory lung fibrosis, bronchiectasis, a neoplastic disease, diabetes mellitus, bronchial asthma, hypothyreosis, mediastinal cyst, or rheumatoid arthritis, optionally, wherein the interstitial lung disease is idiopathic pulmonary fibrosis, sarcoidosis, or proteinosis, and the neoplastic disease is myelofibrosis or lung cancer.

7. The use of claim **1** or **2**, wherein the human previously suffered from tuberculosis.

8. The use of claim **1** or **2**, wherein the non-tuberculosis *Mycobacteria* infection is in the lung of the human, or

wherein the non-tuberculosis *Mycobacteria* infection is in two or more organs in the body, or

wherein the non-tuberculosis *Mycobacteria* infection is in the lymph nodes.

9. The use of claim **1** or **2**, wherein the non-tuberculosis *Mycobacteria* infection or the non-tuberculosis *Mycobacteria*-associated disease is treatment-naïve, or

wherein the non-tuberculosis *Mycobacteria* infection or the non-tuberculosis *Mycobacteria*-associated disease is treatment-refractory.

10. The use of claim **1** or **2**, wherein the non-tuberculosis *Mycobacteria*-associated disease is non-tuberculosis *Mycobacteria*-pulmonary disease, disseminated non-tuberculosis *Mycobacteria* disease, or non-tuberculosis *Mycobacteria*-associated lymphadenitis; or

wherein the non-tuberculosis *Mycobacteria*-associated disease is *Mycobacterium avium* complex (MAC) pulmonary disease, disseminated *Mycobacterium avium* complex (MAC) disease, and *Mycobacterium avium* complex (MAC)-associated lymphadenitis; or

wherein the non-tuberculosis *Mycobacteria*-associated disease is nodular bronchiectasis; or

wherein the non-tuberculosis *Mycobacteria*-associated disease is fibrocavitary.